These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

217 related items for PubMed ID: 9925508

  • 1. Comparative in vitro activities of meropenem, imipenem, temocillin, piperacillin, and ceftazidime in combination with tobramycin, rifampin, or ciprofloxacin against Burkholderia cepacia isolates from patients with cystic fibrosis.
    Bonacorsi S, Fitoussi F, Lhopital S, Bingen E.
    Antimicrob Agents Chemother; 1999 Feb; 43(2):213-7. PubMed ID: 9925508
    [Abstract] [Full Text] [Related]

  • 2. Use of the E test to assess synergy of antibiotic combinations against isolates of Burkholderia cepacia-complex from patients with cystic fibrosis.
    Manno G, Ugolotti E, Belli ML, Fenu ML, Romano L, Cruciani M.
    Eur J Clin Microbiol Infect Dis; 2003 Jan; 22(1):28-34. PubMed ID: 12582741
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Comparison of antibacterial activities of meropenem and six other antimicrobials against Pseudomonas aeruginosa isolates from North American studies and clinical trials.
    Iaconis JP, Pitkin DH, Sheikh W, Nadler HL.
    Clin Infect Dis; 1997 Feb; 24 Suppl 2():S191-6. PubMed ID: 9126693
    [Abstract] [Full Text] [Related]

  • 5. Ciprofloxacin, imipenem and rifampicin: in-vitro synergy of two and three drug combinations against Pseudomonas cepacia.
    Kumar A, Wofford-McQueen R, Gordon RC.
    J Antimicrob Chemother; 1989 Jun; 23(6):831-5. PubMed ID: 2759929
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. In vitro activities of antimicrobial agents, alone and in combinations, against Burkholderia cepacia isolated from blood.
    Lu DC, Chang SC, Chen YC, Luh KT, Hsieh WC.
    Diagn Microbiol Infect Dis; 1997 Aug; 28(4):187-91. PubMed ID: 9327247
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. In Vitro Comparison of Ceftolozane-Tazobactam to Traditional Beta-Lactams and Ceftolozane-Tazobactam as an Alternative to Combination Antimicrobial Therapy for Pseudomonas aeruginosa.
    Goodlet KJ, Nicolau DP, Nailor MD.
    Antimicrob Agents Chemother; 2017 Dec; 61(12):. PubMed ID: 28923865
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. "Switching Partners": Piperacillin-Avibactam Is a Highly Potent Combination against Multidrug-Resistant Burkholderia cepacia Complex and Burkholderia gladioli Cystic Fibrosis Isolates.
    Zeiser ET, Becka SA, Wilson BM, Barnes MD, LiPuma JJ, Papp-Wallace KM.
    J Clin Microbiol; 2019 Aug; 57(8):. PubMed ID: 31167848
    [Abstract] [Full Text] [Related]

  • 13. The efficacy and safety of meropenem and tobramycin vs ceftazidime and tobramycin in the treatment of acute pulmonary exacerbations in patients with cystic fibrosis.
    Blumer JL, Saiman L, Konstan MW, Melnick D.
    Chest; 2005 Oct; 128(4):2336-46. PubMed ID: 16236892
    [Abstract] [Full Text] [Related]

  • 14. In-vitro susceptibility of Haemophilus influenzae to meropenem compared with imipenem, five other beta-lactams, chloramphenicol and ciprofloxacin.
    Powell M, Seetulsingh P, Williams JD.
    J Antimicrob Chemother; 1989 Sep; 24 Suppl A():175-81. PubMed ID: 2808206
    [Abstract] [Full Text] [Related]

  • 15. [Antimicrobial susceptibility of phenotypically extended spectrum beta-lactamase producing Pseudomonas aeruginosa and Acinetobacter baumannii isolates].
    Metan G, Zarakolu P, Hasçelik G, Akova M.
    Mikrobiyol Bul; 2006 Sep; 40(1-2):23-8. PubMed ID: 16775953
    [Abstract] [Full Text] [Related]

  • 16. Evaluation of novel antipseudomonal drugs using the serum bactericidal activity test.
    Braveny I, Machka K, Milatovic D.
    Eur J Clin Microbiol; 1986 Feb; 5(1):119-23. PubMed ID: 3084241
    [Abstract] [Full Text] [Related]

  • 17. In vitro activity of gatifloxacin alone and in combination with cefepime, meropenem, piperacillin and gentamicin against multidrug-resistant organisms.
    Dawis MA, Isenberg HD, France KA, Jenkins SG.
    J Antimicrob Chemother; 2003 May; 51(5):1203-11. PubMed ID: 12697632
    [Abstract] [Full Text] [Related]

  • 18. Potentiation of beta-lactams against Pseudomonas aeruginosa strains by Ro 48-1256, a bridged monobactam inhibitor of AmpC beta-lactamases.
    Livermore DM, Chen HY.
    J Antimicrob Chemother; 1997 Sep; 40(3):335-43. PubMed ID: 9338484
    [Abstract] [Full Text] [Related]

  • 19. Type characterisation and antibiotic susceptibility of Burkholderia (Pseudomonas) cepacia isolates from patients with cystic fibrosis in the United Kingdom and the Republic of Ireland.
    Pitt TL, Kaufmann ME, Patel PS, Benge LC, Gaskin S, Livermore DM.
    J Med Microbiol; 1996 Mar; 44(3):203-10. PubMed ID: 8636938
    [Abstract] [Full Text] [Related]

  • 20. Comparative activity of trovafloxacin, alone and in combination with other agents, against gram-negative nonfermentative rods.
    Visalli MA, Bajaksouzian S, Jacobs MR, Appelbaum PC.
    Antimicrob Agents Chemother; 1997 Jul; 41(7):1475-81. PubMed ID: 9210669
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.